OVERVIEW

Current and Emerging Immunotherapies in Small Cell Lung Cancer (SCLC): Promise and Challenges is organized by Physicians' Education Resource, LLC (PER).

Release Date: November 27, 2019
Expiration Date: November 27, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This continuing medical education (CME) activity is designed to inform physicians about the emerging role of immunotherapy in the treatment of small cell lung cancer (SCLC).

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Describe the benefit of adding immunotherapy to first-line chemotherapy for SCLC
• Discuss the safety of first-line chemo-immunotherapy combination therapy in SCLC
• Analyze the efficacy of immunotherapy in patients with previously treated SCLC

Benefits of Participating:
• Learn expert perspectives on the best strategies for combining immunotherapy with chemotherapy for the treatment of SCLC patients
• Integrate the results of the latest clinical studies into your practice decisions
• Explain safety considerations of chemo-immunotherapy combination therapy in SCLC
• Outline the latest strategies for the use of immunotherapy in patients with previously treated SCLC

Additional details will be posted as soon as information is available.